

A NEW APPROACH TO THE SYNTHESIS OF AMINO IMIDAZOLES
APPLICATION TO THE CEPHALOSPORIN SERIES

F. Jung*, A. Olivier, D. Boucherot


I.C.I. Pharma, Centre de Recherches, Zone Industrielle La Pompelle
B.P. 401, 51064 REIMS CEDEX (FRANCE)

F. Loftus


I.C.I. Pharmaceuticals Division, Process Development Dept
Macclesfield, Cheshire, SK10 4NA (ENGLAND)

Summary : A new, mild approach to amino imidazole 10 starting from the silylated carbodiimide 9 and weakly basic amine 12 is described.


In the course of our work on cephalosporins with novel C-7 heterocyclic substituents, we discovered that the amino imidazole substituent led to compounds possessing particularly interesting biological properties¹. Cephalosporin 1, a potent, β -lactamase stable, orally active compound, was thus selected for extensive biological studies.




A number of approaches to 2-amino imidazoles are known in the literature²; only two proved applicable in the cephalosporin series: the reaction of 2-fluoro imidazoles with 7-amino cephalosporanates, and the condensation of the cyanamide of amino acetaldehyde diethyl acetal with 7-ACA in acidic conditions. However both reactions gave only low yields of 1, the cyanamide approach leading in addition to significant amounts of the isomeric 2-amino imidazole 2¹² which proved difficult to separate from the desired 2-amino imidazole 1¹².




Carbodiimide chemistry was investigated next as a potentially useful approach to these compounds. Carbodiimides substituted by electron withdrawing groups are known to be very reactive electrophiles³. We have synthesized *in situ* carbodiimide **3**^{3,10} and have found that it condenses easily with 7-amino cephalosporin ester **4** at 0°C in CH₂Cl₂, to give the open chain guanidine **5** which possesses all the required structural features for a later transformation into an amino imidazole group. Unfortunately this molecule proved unstable and could not be successfully deprotected in reasonable yield and cyclized to the amino imidazole **6**.



In general, carbodiimides do not condense easily with amines except under vigorous conditions^{4,5}. A few carbodiimidium salts are known, and, not surprisingly, they display a high reactivity towards nucleophiles⁶. It has also been reported that carbodiimides can be condensed, under acid catalysis, with amines of low pK_a⁷. The reactive species here again is probably a charged carbodiimidium salt⁷. 7-Amino cephalosporanates, pK_a = 4.5, fall into the category of weakly basic amines and might therefore condense with carbodiimides under similar conditions. In a model experiment we have indeed been able to condense DCCI with a 7-ACA ester **4** in the presence of hydrogen chloride in CH₂Cl₂ at R.T. to give **8**¹². Under these conditions hydrogen chloride can add to DCCI to give the chloroformamidine **7**¹¹ which can react fairly easily with primary and secondary amines to give the corresponding guanidine⁸. We have also been able to show that this putative intermediate **7**, prepared independently¹¹, is in fact not an intermediate in the condensation, since no reaction between **7** and **4** occurs under these conditions. Not surprisingly in the absence of acid, no reaction occurs between **4** and DCCI. The protonated carbodiimide is therefore most probably the reactive intermediate in the condensation.



We then turned our attention to the silylated carbodiimide 9 which is the ideal intermediate towards the synthesis of amino imidazole 10. In fact, the silylated carbodiimide 9¹² is a stable, distillable (Bp 70° / 0.03 mm Hg) liquid, which was easily prepared from cyanamide 11 by reaction with trimethylsilyl chloride in THF in the presence of triethylamine^{4,9}. As with DCCI, it can be condensed with the silylated ester of 7-ACA 12 in the presence of a strong acid (CF₃SO₃H, H₂SO₄, etc.) in anhydrous CH₂Cl₂ to give the silylated open chain guanidine 13¹². Treatment of this intermediate with concentrated HCl (12 N) 1 eq., at R.T. for 4 hours in CH₃CN gives the amino imidazole 10¹² probably via the intermediates 14 and 15 which have not been isolated.



In conclusion, the above process provides for an efficient (>60% yield), one pot synthesis of 10¹, a key intermediate for the development compound 1 on an industrial scale. We also believe that other amino imidazoles should be easily accessible from weakly basic amines by this procedure.

References

- (1) - Biological properties of these compounds will be published elsewhere, see also the preceding paper.
- (2) - G.C. LANZINI, E. LAZZARI, J. Het. Chem. 1966, 3, 152
 - Imidazole and its Derivatives, K. HOFMANN, The Chemistry of Heterocyclic Compounds, John Wiley, 1953, part I
 - M.R. GRIMMETT, Adv. Het. Chem. 1970, 12, 103
 - New routes to the synthesis of 2-amino imidazoles are described in the preceding paper.

- (3) - J. GOERDELER, S. RADDATZ, Chem. Ber. 1980, 113, 1095
 - R. NEIDLEIN, E. HEUKELBACH, Arch. Pharm. 1966, 299, 709
 - R. NEIDLEIN, E. HEUKELBACH, Tetrahedron Lett. 1965, 149
 - E. SCHAUMANN, E. KAUSCH, Liebigs Ann. Chem. 1978, 1560
- (4) - F. KURZER, K. DOURAGHI-ZADEH, Chem. Rev. 1967, 67, 107
- (5) - A. WILLIAMS, I.T. IBRAHIM, Chem. Rev. 1981, 81, 589
- (6) - J.C. JOCHIMS, R. ABU-EL-HALAWA, L. ZSOLNAI, G. HUTTNER, Chem. Ber. 1984, 117, 1161
- (7) - K. HARTKE, M. RADAV, Arch. Pharm. 1972, 305, 708
- (8) - "The Chemistry of Imidoyl Halides", H. ULRICH, Plenum Press 1968
- (9) - I. RUPPERT, Angew. Chem. Int. Ed. Engl. 1977, 16, 311
- (10) - 3 was obtained from the corresponding thiourea by reaction with yellow mercuric chloride, sulfur, in acetonitrile, in the presence of 4 to give directly the fairly unstable cephalosporin 5.
 $^1\text{H-NMR}$, 90 MHz, CDCl_3 , δ ppm : 1.1, t ($J = 7.2$ Hz), 6H ; 1.4, s, 18H ; 2.04, s, 3H ; 3.1-3.8, m, 8H ; 4.34, d ($J = 4$ Hz), 1H ; 4.6, dd ($J = 4$ Hz, 7.7 Hz), 1H ; 4.86, t ($J = 6$ Hz), 1H. IR, KBr : 1770, 1720, 1620 cm^{-1} .
- (11) - Obtained by addition of one equivalent of HCl to a solution of DCCI in CHCl_3 at R.T.
- (12) 1 Anal. C, H, N, S. $^1\text{H-NMR}$, 90 MHz, DMSO d_6 , TFA d , δ ppm : 3.51, 3.74, AB ($J = 18.5$ Hz), 2H ; 3.88, 4.08, AB ($J = 12.8$ Hz), 2H ; 5.1, 5.5, AB ($J = 4.3$ Hz) ; 7.08, s, 2H ; 7.87, s, 1H. IR, KBr : 1770, 1680 cm^{-1} .
- 2 $^1\text{H-NMR}$, 90 MHz, DMSO d_6 , CD_3COOD , δ ppm : 3.43, 3.8, AB ($J = 19.2$ Hz), 2H ; 3.95, 4.2, AB ($J = 13.8$ Hz), 2H ; 5.17, 6.05, AB ($J = 4.6$ Hz), 2H ; 6.7, 6.8, AB ($J = 2.7$ Hz), 2H ; 7.8, s, 1H.
- 8 $^1\text{H-NMR}$, 90 MHz, DMSO d_6 , TFA d , δ ppm : 0.7-2, m, 20H ; 1.45, s, 9H ; 1.95, s, 3H ; 3.2-3.8, m, 4H ; 5.15, 5.65, AB ($J = 4.5$ Hz), 2H. IR, KBr : 1760, 1720, 1635, 1610 cm^{-1} .
- 9 $^1\text{H-NMR}$, 90 MHz, CDCl_3 , δ ppm : 0.2, s, 9H ; 1.2, t ($J = 7$ Hz), 6H ; 3.24, d ($J = 5$ Hz), 2H ; 3.4-3.8, m, 4H ; 4.5, t ($J = 5$ Hz), 1H. IR, CH_2Cl_2 : 2170 cm^{-1} .
- 10 Anal. C, H, N, S. $^1\text{H-NMR}$, 90 MHz, DMSO d_6 , TFA d , δ ppm : 2.0, s, 3H ; 3.45, 3.65, AB ($J = 19.2$ Hz), 2H ; 4.74, 5.06, AB ($J = 12.8$ Hz), 2H ; 5.2, 5.6, AB ($J = 4.4$ Hz), 2H ; 7.04, s, 2H. IR, KBr : 1780, 1735, 1660 cm^{-1} .
- 13 $^1\text{H-NMR}$, 90 MHz, CDCl_3 , δ ppm : 0, s, 9H ; 0.25, s, 9H ; 1.05, t ($J = 6.4$ Hz), 6H ; 1.95, s, 3H ; 3.0-3.8, m, 8H ; 4.45, t ($J = 3.8$ Hz), 1H ; 4.8, 5.15, AB ($J = 14$ Hz), 2H ; 5.15, d ($J = 4.5$ Hz), 1H ; 5.5, dd ($J = 4.5$ Hz, 7.7 Hz), 1H. IR, CH_2Cl_2 : 1785, 1735, 1700, 1670 cm^{-1} .

(Received in France 23 January 1989)